uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Impact of body mass index on the efficacy of endocrine therapy in patients with metastatic breast cancer - A retrospective two-center cohort study
Orebro Univ, Inst Med Sci, Campus USO, S-70182 Orebro, Sweden.
Akad Univ Hosp, Dept Oncol, Uppsala, Sweden.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD). Malarsjukhuset, Dept Oncol, Eskilstuna, Sweden.
2018 (English)In: Breast, ISSN 0960-9776, E-ISSN 1532-3080, Vol. 40, p. 136-140Article in journal (Refereed) Published
Abstract [en]

Bakground: The aim of this study was to investigate the impact of body mass index (BMI) on the efficacy of endocrine therapy in postmenopausal women with metastatic hormone receptor breast cancer (HR+BC) as well as to identify if the potential difference in efficacy was associated with Fulvestrant only or both aromatase inhibitors (AIs) and Fulvestrant. Methods: A consecutive cohort of postmenopausal women with HR+metastatic breast cancer that have received endocrine therapy including Fulvestrant as a metastatic treatment strategy at the Departments of Oncology in Eskilstuna and Uppsala, Sweden, between 2008 and 2016 were identified. The primary outcome of the study was time to disease progression (TTP) during the treatment with Fulvestrant in overweight and obese women compared to patient with normal BMI. Results: In total, 173 patients were enrolled in the study cohort, amongst these, 141 patients received both Fulvestrant and Als and 32 received only Fulvestrant. No statistical significant association was observed between the three BMI categories and TTP, during Fulvestrant treatment (p = 0.136). The rates of objective response and clinical benefit due to Fulvestrant were similar among patients with normal weight, overweight and obesity, respectively. Conclusions: No difference in treatment efficacy was seen between normal, overweight and obese women with metastatic HR+BC, when treated with Fulvestrant. Until further research with prospective studies is available, there is no evidence to support any modification in how Fulvestrant treatment is used in patients with metastatic breast cancer in regard to BMI.

Place, publisher, year, edition, pages
CHURCHILL LIVINGSTONE , 2018. Vol. 40, p. 136-140
Keywords [en]
Metastatic breast cancer, Efficacy, Endocrine treatment, Fulvestrant, Obesity, BMI
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-361675DOI: 10.1016/j.breast.2018.05.005ISI: 000438382800022PubMedID: 29783185OAI: oai:DiVA.org:uu-361675DiVA, id: diva2:1254134
Available from: 2018-10-08 Created: 2018-10-08 Last updated: 2018-10-08Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Valachis, Antonis

Search in DiVA

By author/editor
Valachis, Antonis
By organisation
Centrum för klinisk forskning i Sörmland (CKFD)
In the same journal
Breast
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 13 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf